Opponents say the "beach closures to facilitate the very risky, hazardous activity puts the public in danger." 

A surprising obesity trial result has shaken confidence in Novo Nordisk (NVO +1.38%) and sharpened the spotlight on Eli Lilly (LLY 2.03%) in this fiercely competitive GLP‑1 race. Watch the video below to see what it could mean for investors. *This video was published on Feb.24, 2026. Andy Cross has no position in any of...